Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS

Christopher H. Yee, Zongyu Zheng, Lauren Shuman, Hironobu Yamashita, Joshua Warrick, Xue Ru Wu, Jay Raman, David Degraff

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tumorigenesis requires accumulation of genetic and epigenetic alterations, some of which drive tumor initiation. “Oncogene addiction” describes the phenomenon that (1) well-established cancers are dependent on one mutated oncogene or pathway for the maintenance of a malignant phenotype and that (2) withdrawal of the single oncogenic event leads to growth arrest and/or cancer regression. While oncogene addiction has been experimentally validated in advanced tumor models, its role in tumor precursors has not been investigated. We utilized the requirement of Forkhead box A1 (Foxa1) for transcriptional activation of the Upk2-promoter to temporally control the expression of Upk2-HRAS* oncogene, an inducer of urothelial hyperplasia in transgenic mice. Inducible homozygous knockout of Foxa1 in Upk2-HRAS*/UBC-Cre ERT2 /Foxa1 loxp/loxp mice results in reduced HRAS* levels. This led to a marked reduction of urothelial proliferation as evidenced by urothelial thinning, degenerative changes such as intracellular vacuole formation, and reduced Ki67 expression. Reduced proliferation did not affect basal, Krt14-positive cells, supporting the fact that Foxa1-regulated Upk2-HRAS* expression occurs primarily in supra-basal cells. Our results indicate that maintenance of urothelial hyperplasia in Upk2-HRAS* mice depends on continuous expression of Foxa1 and activated HRAS, and that mutated receptor tyrosine kinases, FOXA1 and/or other downstream effectors may mediate oncogene addiction in urothelial hyperplasia.

Original languageEnglish (US)
Article number270
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Oncogenes
Urinary Bladder Neoplasms
Hyperplasia
Maintenance
Neoplasms
Receptor Protein-Tyrosine Kinases
Vacuoles
Epigenomics
Transgenic Mice
Transcriptional Activation
Carcinogenesis
Phenotype
Growth

All Science Journal Classification (ASJC) codes

  • General

Cite this

@article{e0410f6bafc84d98b67020ce035b0128,
title = "Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS",
abstract = "Tumorigenesis requires accumulation of genetic and epigenetic alterations, some of which drive tumor initiation. “Oncogene addiction” describes the phenomenon that (1) well-established cancers are dependent on one mutated oncogene or pathway for the maintenance of a malignant phenotype and that (2) withdrawal of the single oncogenic event leads to growth arrest and/or cancer regression. While oncogene addiction has been experimentally validated in advanced tumor models, its role in tumor precursors has not been investigated. We utilized the requirement of Forkhead box A1 (Foxa1) for transcriptional activation of the Upk2-promoter to temporally control the expression of Upk2-HRAS* oncogene, an inducer of urothelial hyperplasia in transgenic mice. Inducible homozygous knockout of Foxa1 in Upk2-HRAS*/UBC-Cre ERT2 /Foxa1 loxp/loxp mice results in reduced HRAS* levels. This led to a marked reduction of urothelial proliferation as evidenced by urothelial thinning, degenerative changes such as intracellular vacuole formation, and reduced Ki67 expression. Reduced proliferation did not affect basal, Krt14-positive cells, supporting the fact that Foxa1-regulated Upk2-HRAS* expression occurs primarily in supra-basal cells. Our results indicate that maintenance of urothelial hyperplasia in Upk2-HRAS* mice depends on continuous expression of Foxa1 and activated HRAS, and that mutated receptor tyrosine kinases, FOXA1 and/or other downstream effectors may mediate oncogene addiction in urothelial hyperplasia.",
author = "Yee, {Christopher H.} and Zongyu Zheng and Lauren Shuman and Hironobu Yamashita and Joshua Warrick and Wu, {Xue Ru} and Jay Raman and David Degraff",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-36720-6",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS. / Yee, Christopher H.; Zheng, Zongyu; Shuman, Lauren; Yamashita, Hironobu; Warrick, Joshua; Wu, Xue Ru; Raman, Jay; Degraff, David.

In: Scientific reports, Vol. 9, No. 1, 270, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS

AU - Yee, Christopher H.

AU - Zheng, Zongyu

AU - Shuman, Lauren

AU - Yamashita, Hironobu

AU - Warrick, Joshua

AU - Wu, Xue Ru

AU - Raman, Jay

AU - Degraff, David

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Tumorigenesis requires accumulation of genetic and epigenetic alterations, some of which drive tumor initiation. “Oncogene addiction” describes the phenomenon that (1) well-established cancers are dependent on one mutated oncogene or pathway for the maintenance of a malignant phenotype and that (2) withdrawal of the single oncogenic event leads to growth arrest and/or cancer regression. While oncogene addiction has been experimentally validated in advanced tumor models, its role in tumor precursors has not been investigated. We utilized the requirement of Forkhead box A1 (Foxa1) for transcriptional activation of the Upk2-promoter to temporally control the expression of Upk2-HRAS* oncogene, an inducer of urothelial hyperplasia in transgenic mice. Inducible homozygous knockout of Foxa1 in Upk2-HRAS*/UBC-Cre ERT2 /Foxa1 loxp/loxp mice results in reduced HRAS* levels. This led to a marked reduction of urothelial proliferation as evidenced by urothelial thinning, degenerative changes such as intracellular vacuole formation, and reduced Ki67 expression. Reduced proliferation did not affect basal, Krt14-positive cells, supporting the fact that Foxa1-regulated Upk2-HRAS* expression occurs primarily in supra-basal cells. Our results indicate that maintenance of urothelial hyperplasia in Upk2-HRAS* mice depends on continuous expression of Foxa1 and activated HRAS, and that mutated receptor tyrosine kinases, FOXA1 and/or other downstream effectors may mediate oncogene addiction in urothelial hyperplasia.

AB - Tumorigenesis requires accumulation of genetic and epigenetic alterations, some of which drive tumor initiation. “Oncogene addiction” describes the phenomenon that (1) well-established cancers are dependent on one mutated oncogene or pathway for the maintenance of a malignant phenotype and that (2) withdrawal of the single oncogenic event leads to growth arrest and/or cancer regression. While oncogene addiction has been experimentally validated in advanced tumor models, its role in tumor precursors has not been investigated. We utilized the requirement of Forkhead box A1 (Foxa1) for transcriptional activation of the Upk2-promoter to temporally control the expression of Upk2-HRAS* oncogene, an inducer of urothelial hyperplasia in transgenic mice. Inducible homozygous knockout of Foxa1 in Upk2-HRAS*/UBC-Cre ERT2 /Foxa1 loxp/loxp mice results in reduced HRAS* levels. This led to a marked reduction of urothelial proliferation as evidenced by urothelial thinning, degenerative changes such as intracellular vacuole formation, and reduced Ki67 expression. Reduced proliferation did not affect basal, Krt14-positive cells, supporting the fact that Foxa1-regulated Upk2-HRAS* expression occurs primarily in supra-basal cells. Our results indicate that maintenance of urothelial hyperplasia in Upk2-HRAS* mice depends on continuous expression of Foxa1 and activated HRAS, and that mutated receptor tyrosine kinases, FOXA1 and/or other downstream effectors may mediate oncogene addiction in urothelial hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=85060400183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060400183&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-36720-6

DO - 10.1038/s41598-018-36720-6

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 270

ER -